Article
Oncology
L. Paz-Ares, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, M. J. Hochmair, M. Ozguroglu, J. H. Ji, M. C. Garassino, O. Voitko, A. Poltoratskiy, E. Musso, L. Havel, I Bondarenko, G. Losonczy, N. Conev, H. Mann, T. B. Dalvi, H. Jiang, J. W. Goldman
Summary: In extensive-stage small-cell lung cancer (ES-SCLC), durvalumab plus EP continues to improve overall survival (OS), while durvalumab plus tremelimumab plus EP shows numerical improvement but does not reach statistical significance.
Article
Oncology
Katsuyuki Hotta, Makoto Nishio, Haruhiro Saito, Isamu Okamoto, Yasuharu Nakahara, Hidetoshi Hayashi, Manabu Hayama, Peter Laud, Haiyi Jiang, Luis Paz-Ares, Koichi Azuma
Summary: The first-line treatment of durvalumab plus EP demonstrated efficacy and good tolerability in Japanese patients with ES-SCLC. Despite the small sample size of the Japan subgroup, the results were generally consistent with the global study population.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Tetsuhiko Asao, Satoshi Watanabe, Takahiro Tanaka, Satoshi Morita, Kunihiko Kobayashi
Summary: This study aims to assess the safety and efficacy of carboplatin and etoposide plus durvalumab in patients with ES-SCLC and a poor PS.
Article
Immunology
Jun Ni, Xiaoyan Si, Hanping Wang, Xiaotong Zhang, Li Zhang
Summary: This study evaluates the preliminary efficacy and safety of camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer (ES-SCLC) patients. The results show that IP/IC plus camrelizumab group has a median PFS of 10.25 months, and the objective response rate is 89.6%.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Dmytro Trukhin, Galina Statsenko, Maximilian J. Hochmair, Mustafa Ozguroglu, Jun Ho Ji, Marina Chiara Garassino, Oleksandr Voitko, Artem Poltoratskiy, Santiago Ponce, Francesco Verderame, Libor Havel, Igor Bondarenko, Andrzej Kazarnowicz, Gyorgy Losonczy, Nikolay V. Conev, Jon Armstrong, Natalie Byrne, Piruntha Thiyagarajah, Haiyi Jiang, Luis Paz-Ares
Summary: The study showed that first-line treatment with durvalumab plus platinum-etoposide resulted in sustained improvement in overall survival, while the addition of tremelimumab to this combination did not significantly enhance efficacy. These findings support the use of durvalumab plus platinum-etoposide as a new standard of care for extensive-stage small-cell lung cancer.
Article
Oncology
Lijuan Li, Dan Yang, Yanmei Min, Anyan Liao, Jing Zhao, Leilei Jiang, Xin Dong, Wei Deng, Huiming Yu, Rong Yu, Jun Zhao, Anhui Shi
Summary: This study aimed to assess the safety and efficacy of chemoimmunotherapy combined with thoracic radiotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC). A total of 36 patients with ES-SCLC received this treatment modality at one hospital. The results showed that this treatment approach is safe and has good survival outcomes.
Article
Oncology
Tiandong Kong, Lu Chen, Xiaoli Zhao, Fangfang Duan, Hanli Zhou, Lei Wang, Danna Liu
Summary: This study assessed the efficacy and safety of adding anlotinib to platinum-chemotherapy as first-line therapy for patients with extensive-stage small-cell lung cancer (ES-SCLC). The results showed that this combination therapy has anti-tumor activity and acceptable tolerability, providing a basis for future randomized controlled trials.
INVESTIGATIONAL NEW DRUGS
(2022)
Article
Oncology
Jie Wang, Caicun Zhou, Wenxiu Yao, Qiming Wang, Xuhong Min, Gongyan Chen, Xingxiang Xu, Xingya Li, Fei Xu, Yong Fang, Runxiang Yang, Guohua Yu, Youling Gong, Jun Zhao, Yun Fan, Quan Liu, Lejie Cao, Yu Yao, Yunpeng Liu, Xiaoling Li, Jingxun Wu, Zhiyong He, Kaihua Lu, Liyan Jiang, Chengping Hu, Wenhua Zhao, Ben Zhang, Wei Shi, Xiaojing Zhang, Ying Cheng
Summary: The study evaluated the efficacy and safety of adebrelimab in combination with standard chemotherapy as a first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). The results showed that the addition of adebrelimab significantly improved overall survival and had an acceptable safety profile. Therefore, the combination of adebrelimab and chemotherapy may be a new treatment option for ES-SCLC patients.
Review
Oncology
Bryan Oronsky, Nacer Abrouk, Scott Caroen, Michelle Lybeck, Xiaoning Guo, Xiaohui Wang, Zhongwen Yu, Tony Reid
Summary: For close to 40 years, small-cell lung cancer (SCLC) has been stagnant with no progress or effective treatments. However, between 2018 and 2021, several new drugs were approved, bringing hope to SCLC patients.
Article
Oncology
Martin Reck, Tony S. K. Mok, Aaron Mansfield, Richard De Boer, Gyorgy Losonczy, Shunichi Sugawara, Rafal Dziadziuszko, Maciej Krzakowski, Alexey Smolin, Maximilian Hochmair, Marina Chiara Garassino, Gilberto de Castro Junior, Helge Bischoff, Sivuonthanh Lam, Andres Cardona, Stefanie Morris, Stephen Liu
Summary: The IMpower133 study demonstrated that atezolizumab in combination with carboplatin and etoposide improved overall survival and progression-free survival in first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). Further analysis revealed that the benefits of atezolizumab maintenance therapy persisted after adjusting for baseline characteristics, and the safety profile was similar to the placebo group.
JOURNAL OF THORACIC ONCOLOGY
(2022)
Review
Oncology
Zaina T. Al-Salama
Summary: Durvalumab, a fully human monoclonal antibody against PD-L1, when used in combination with chemotherapy in first-line treatment of extensive-stage small cell lung cancer, has shown significantly longer overall survival, higher objective response rate, and manageable tolerability profile. This combination therapy represents a valuable treatment option and an accepted standard of care for these patients.
Article
Oncology
Yun Fan, Jun Zhao, Qiming Wang, Dingzhi Huang, Xingya Li, Jianhua Chen, Yong Fang, Jianchun Duan, Caicun Zhou, Yanping Hu, Haihua Yang, Yi Hu, Jianying Zhou, Xiaoyan Lin, Lifeng Wang, Zhijie Wang, Yanjun Xu, Tao Zhang, Wei Shi, Jianjun Zou, Jie Wang
Summary: The study demonstrated potential antitumor activity of camrelizumab plus apatinib in patients with ED-SCLC who had failed platinum-based chemotherapy, including those who were chemotherapy-sensitive and chemotherapy-resistant. Treatment-related adverse events of grade 3 or higher were reported in a significant proportion of patients, leading to treatment discontinuation in some cases. Further clinical studies are warranted to explore the efficacy of this combination therapy in SCLC.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Christine L. Hann, Timothy F. Burns, Afshin Dowlati, Daniel Morgensztern, Patrick J. Ward, Martina M. Koch, Chris Chen, Carrianne Ludwig, Maulik Patel, Halla Nimeiri, Philip Komarnitsky, D. Ross Camidge
Summary: This study evaluated different doses and combination strategies of Rova-T in patients with extensive-stage SCLC, finding that lower doses may be associated with a lower incidence of some adverse reactions, but adding Rova-T to platinum-based chemotherapy did not show significant efficacy benefit.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Article
Oncology
Shen Lin, Shaohong Luo, Dian Gu, Meiyue Li, Xin Rao, Changlian Wang, Pinfang Huang, Xiongwei Xu, Xiuhua Weng
Summary: The study evaluated the cost-effectiveness of adding durvalumab to EP for ES-SCLC patients from the U.S. payer perspective. Results showed that although DEP increased survival compared to EP, it was not cost-effective. Lowering the price of durvalumab may improve the economic feasibility of DEP.
Article
Oncology
Emanuele Vita, Alessio Stefani, Geny Piro, Luca Mastrantoni, Marco Cintoni, Giuseppe Cicchetti, Ileana Sparagna, Federico Monaca, Guido Horn, Jacopo Russo, Diletta Barone, Mariantonietta Di Salvatore, Rocco Trisolini, Filippo Lococo, Ciro Mazzarella, Alessandra Cancellieri, Carmine Carbone, Anna Rita Larici, Maria Cristina Mele, Sara Pilotto, Michele Milella, Giampaolo Tortora, Emilio Bria
Summary: Leptin may play a crucial role in the effectiveness of immunotherapy in lung adenocarcinoma, and is associated with metabolic immune dysfunctions.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
